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In this issue of Cell Stem Cell, Feng et al. (2013) report that the gene mutated in human CHARGE syndrome,
ATP-dependent chromatin remodeling factor CHD7, contributes to the control of neurogenesis. The authors
also report that exercise ameliorates these defects and suggest it as an intervention worthy of study in
CHARGE syndrome.Progressive compaction of DNA wrapped
around histone octamers to form nucle-
osomes and higher-order chromatin
structures constitutes an organizational
mechanism for DNA storage. However,
this compaction also presents barriers
to gene expression because the trans-
criptional machinery requires access to
DNA. Consequently, dynamic modulation
of DNA accessibility by chromatin remod-
eling complexes is an important mech-
anism for controlling cell fate during
development and, when deregulated,
causing disease. In this issue of Cell
Stem Cell, Feng et al. (2013) seek to char-
acterize the contributions of CHD7, an
ATP-dependent chromatin remodeler, to
developmental and adult neurogenesis.
Chromatin modifiers can be organized
into two classes that contribute to tran-
scriptional regulation, those that cova-
lently modify histones and those that
utilize the energy of ATP hydrolysis
to mobilize nucleosomes and remodel
chromatin structure. Mutations in genes
encoding chromatin remodelers are
increasingly recognized as frequently
occurring in cancer (Wilson and Rob-
erts, 2011), but they are also linked
with developmental disorders. Some of
these include ERCC6 in cerebro-oculo-
facio-skeletal syndrome, ATRX in ATRX-
syndrome and a-thalassemia myelo-
dyspasia syndrome, genes encoding
subunits of the SWI/SNF (BAF) chro-
matin remodeling complex in Coffin-
Siris syndrome (Tsurusaki et al.,
2012), and CHD7 in CHARGE syn-
drome (Clapier and Cairns, 2009).
The CHD (chromodomain-helicase-DNA-
binding protein) family is a subclass of
ATP-dependent remodelers. De novo het-
erozygous mutations of CHD7 are theprincipal cause of the complex develop-
mental disorder CHARGE syndrome,
characterized, in addition to other anoma-
lies, by olfactory defects and mental
retardation (Bergman et al., 2011). Homo-
zygous inactivation of Chd7 in mice re-
sults in embryonic lethality at day E10.5
while heterozygous mutations produce
phenotypes similar to human CHARGE,
including postnatal growth delay, vestib-
ular dysfunction, and olfactory defects
(Bosman et al., 2005; Hurd et al., 2007).
However, the mechanisms by which mu-
tation of this chromatin remodeler result
in specific developmental defects are
poorly understood.
In this issue of Cell Stem Cell, Feng
et al. (2013) investigate how CHD7
contributes to regulation of adult neu-
rogenesis. They show that CHD7 ex-
pression is highly enriched in the
subventricular zone and subgranular
zone (SVZ and SGZ), two neurogenic
areas of the mammalian brain. They
demonstrate that CHD7 expression,
although not present in quiescent
neural stem cells (NSCs), increases in
active NSCs, peaks in transit-amplifying
progenitors, and persist in neuroblasts.
The authors next inactivate Chd7 in Tlx-
or Nestin-expressing neural stem cells
(NSCs) using Chd7 conditional mice and
find that deletion of CHD7 leads to
decrease of both SVZ and hippocampal
neurogenesis. Loss of CHD7 is shown to
have no effect upon NSC self-renewal
but instead blocks differentiation, thus
inhibiting neurogenesis. Consequently,
CHD7 is dispensable for the maintenance
of NSC populations, but essential for
differentiation into neural populations.
Notably, the authors find that voluntary
running is able to rescue the reduced hip-Cell Stempocampal neurogenesis of the CHD7
mutant mice.
To investigate the mechanistic basis for
the contributions of CHD7 to NSC differ-
entiation, the authors searched for genes
whose expression most parallels that of
CHD7 itself, reasoning that such genes
may be enriched for direct targets of this
chromatin remodeler. Using The Cancer
Genome Atlas (TCGA), two transcription
factors essential for neuronal identity,
Sox4 and Sox11, were identified as most
highly correlated with CHD7 expression.
The promoters of these genes were then
identified as bound by CHD7. The authors
also show that these genes are activated
via CHD7 contributions to decompaction
of nucleosomes at their promoters. A
central role for Sox4 and Sox11 is sug-
gested by the finding that forced expres-
sion of these genes circumvents the
differentiation blockade resulting from
CHD7 loss.
Collectively, the work of Feng et al.
identify CHD7 as a regulator of neurogen-
esis that directly controls the acquisition
of neural fate by regulating expression of
transcription factors Sox4 and Sox11
(Figure 1). Given that chromatin remodel-
ing factors are typically capable of inter-
acting with many regulatory proteins
(Batsukh et al., 2010), it will be of interest
to determine how CHD7 is targeted to
Sox4 and Sox11 promoters and whether
it contributes to other aspects of chro-
matin structure at these targets.
Perhaps one of the most provocative
findings by Feng et al. is the amelioration
of the CHD7 loss phenotype brought
about by physical exercise. Exercise
has been shown to have stimulatory
effects upon neurotransmitters and to
increase survival of nascent neurons inCell 13, July 3, 2013 ª2013 Elsevier Inc. 1
Figure 1. CHD7 and Physical Exercise in CHARGE Syndrome
CHD7 functions as a regulator of neurogenesis via direct binding to the promoters of fate-controlling
transcription factors to facilitate open chromatin structure. Feng et al. show that exercise may ameliorate
the neurogenic defects otherwise caused by CHD7 mutation.
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Previewsthe SGZ zone in Parkinson’s disease
models (Frazzitta et al., 2013), a zone in
which neurogenesis is impaired follow-
ing CHD7 loss. Via the provision of an
exercise wheel, the authors therefore
examine the effects of voluntary running
upon the number of neurons and dendrite
development, both of which are nega-
tively affected by CHD7 mutation. Strik-
ingly, they report that exercise results in
improvement of both phenotypes. While
the CHD7 findings could raise the possi-
bility of exercise being used as a therapy
for patients with CHARGE syndrome,2 Cell Stem Cell 13, July 3, 2013 ª2013 Elsevthe findings by Feng et al. must be consid-
ered preliminary until they can be tested
for reproducibility. Nonetheless, further
investigation in mouse models should
be pursued and, if confirmed, may war-
rant consideration of human studies. It
should be kept in mind that the pheno-
typic changes characterized here arose
from targeted knockout of CHD7 in a
mature NSC population. It will be of inter-
est to determine whether similar inter-
actions occur in other tissues affected
in CHARGE syndrome and also how
CHD7 interacts with other chromatinier Inc.modifiers and transcription factors to
regulate transcription. Gaining a deeper
understanding of the molecular func-
tion of CHD7 should provide insight
into CHARGE syndrome, and perhaps
other chromatin-based diseases, and
may offer clues for novel approaches to
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